Workflow
奥赛康(002755) - 2020 Q1 - 季度财报
ASK PHARMASK PHARM(SZ:002755)2020-04-29 16:00

Financial Performance - The company's revenue for Q1 2020 was ¥709,235,498.92, a decrease of 36.31% compared to ¥1,113,535,599.62 in the same period last year[8] - Net profit attributable to shareholders was ¥106,515,696.82, down 43.35% from ¥188,023,269.18 year-on-year[8] - Basic and diluted earnings per share were both ¥0.11, representing a decline of 45.00% from ¥0.20 in the same period last year[8] - Revenue decreased by 36.31% to ¥709,235,498.92 from ¥1,113,535,599.62, primarily impacted by the pandemic[17] - Net profit fell by 43.43% to ¥106,166,637.56 from ¥187,667,348.88, corresponding to the decrease in revenue[17] - Total operating revenue for the first quarter was 120,641,827.61 CNY, a decrease from 212,489,202.56 CNY in the previous year, representing a decline of approximately 43%[56] - Net profit for the first quarter was 106,166,637.56 CNY, down from 187,667,348.88 CNY year-over-year, indicating a decrease of about 43%[56] - The total profit for the first quarter was 125,358,845.71 CNY, down from 221,822,510.32 CNY, indicating a decline of approximately 43%[56] Cash Flow - The net cash flow from operating activities increased significantly by 356.10%, reaching ¥172,458,289.64 compared to ¥37,811,213.57 in the previous year[8] - Cash inflow from operating activities totaled 1,040,373,771.94 yuan, down from 1,236,329,186.71 yuan in the previous period, representing a decrease of approximately 15.8%[67] - Cash outflow from operating activities was 867,915,482.30 yuan, compared to 1,198,517,973.14 yuan in the previous period, a reduction of about 27.5%[70] - Net cash flow from operating activities was 172,458,289.64 yuan, significantly higher than 37,811,213.57 yuan in the previous period, marking an increase of approximately 355.5%[70] - Cash flow from investing activities resulted in a net outflow of -52,459,968.67 yuan, an improvement from -69,397,885.47 yuan in the previous period[74] Assets and Liabilities - Total assets at the end of the reporting period were ¥3,558,334,737.04, a decrease of 3.62% from ¥3,692,097,041.59 at the end of the previous year[8] - Total liabilities decreased from ¥1,175,525,356.82 to ¥935,507,760.67, a reduction of approximately 20.4%[43] - Current liabilities decreased from ¥1,078,722,487.48 to ¥836,965,965.83, a decline of about 22.4%[40] - Total current assets as of December 31, 2019, were CNY 2,634,917,442.23, remaining unchanged as of January 1, 2020[80] - Total non-current assets were CNY 1,057,179,599.36 as of December 31, 2019, also unchanged as of January 1, 2020[80] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 19,292[12] - The largest shareholder, Nanjing Aosaikang Investment Management Co., Ltd., held 34.20% of the shares, totaling 317,470,588 shares[12] Expenses - Research and development expenses amounted to 47,836,244.95 CNY, compared to 62,466,341.81 CNY in the previous year, reflecting a reduction of approximately 23%[56] - Sales expenses were reported at 430,650,515.20 CNY, down from 686,935,771.85 CNY, marking a decrease of around 37%[56] - The company recorded a financial expense of -3,170,263.18 CNY, compared to -1,527,505.88 CNY in the previous year, reflecting an increase in financial costs[56] - The company’s tax expenses were 19,192,208.15 CNY, down from 34,155,161.44 CNY, showing a decrease of about 44%[56] - The company’s total operating costs were 592,159,611.81 CNY, down from 900,214,072.07 CNY, representing a reduction of approximately 34%[56] Changes in Accounting Standards - The company has implemented new revenue and leasing standards starting in 2020, with retrospective adjustments for prior comparative data[88] - A reclassification adjustment reduced advance receipts by CNY 62,457,242.16 and increased contract liabilities by CNY 55,271,895.72 due to the new revenue recognition standards[84] - The company reclassified prepayments to contract liabilities and other current liabilities under new revenue standards, resulting in a contract liability of ¥16,269,146.90[17]